CytoDyn

CytoDyn is a biotechnology company dedicated to enhancing the lives of patients with life-threatening diseases. The company is currently in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. Leronlimab, a humanized monoclonal antibody, is administered as a once-a-week subcutaneous injection and can also be given intravenously. It competitively binds to the CCR5 receptor, setting it apart from other CCR5 antagonists.

Established in 2002, CytoDyn operates in the biotechnology, health and wellness, and pharmaceutical industries. The company recently secured a Post-IPO Equity investment on 15 September 2021, indicating ongoing support and interest in its groundbreaking work. The specific details of this investment, including the amount and the involved investors, have not been disclosed.